Printer Friendly

InterHealth's OptiBerry[TM] shown to inhibit angiogenesis.

Recent studies published in peer reviewed journals have shown that OptiBerry[TM], a patent-pending, standardized multiple berry extract developed by InterHealth Nutraceuticals, possesses potent anti-angiogenic properties, which inhibit the growth of unwanted blood vessels involved in the formation of tumors and varicose veins. Researchers at The Ohio State University Medical Center, Columbus, OH, University of Kupio, Kupio, Finland and Creighton University Medical Center, Omaha, NE, have shown that OptiBerry significantly inhibits angiogenesis both in vitro and in vivo, thus offering potential benefit in the treatment of related disorders such as cancer and inflammation. The studies were published in Free Radical Research and the Federation of European Biochemical Societies (FEBS) Letters. OptiBerry contains numerous berry extracts, including wild blueberry, bilberry, cranberry, elderberry, raspberry and strawberry.

For further information: 707-751-2801.
COPYRIGHT 2003 Rodman Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Highlights
Publication:Nutraceuticals World
Article Type:Brief Article
Geographic Code:1USA
Date:Sep 1, 2003
Words:128
Previous Article:Positive test results for new DSM recovery drink.
Next Article:PET product range; polyester films.
Topics:


Related Articles
ENTREMED GETS GENE PATENT FOR ANGIOSTATIN PROTEIN
EntreMed Research emphasizing low-dose cancer therapy featured at cancer research meeting.
InterHealth Nutraceuticals: committed to research & education. (Supply Scource).
To the editor. (Industry News).
InterHealth Nutraceuticals. (2003 Nutraceuticals World Company Capabilities).
Progen granted anti-angiogenesis antibody patent.
InterHealth Nutraceuticals.
Bionomic's gene silencing molecules inhibitor tumor growth in breast cancer model.
Bionomics files further patents for BNO69 cancer target.
InterHealth Nutraceuticals, Inc.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters